Shares of Day One Biopharmaceuticals, Inc. (DAWN) have gained 22.5% over the past four weeks to close the last trading session at $10.73, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$22.25 indicates a potential upside of 107.4%.The mean estimate comprises eight short-term price targets with a standard deviation of $4.86. While the lowest estimate of$16.00 indicates a 49.1% ...